Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.

Abstract

Hepatitis B and C viruses (HBV and HCV), both cause serious chronic infections leading to fatal liver diseases. The prototype therapy for both HBV and HCV was based on IFN-α with or without ribavirin. The advent of direct-acting antivirals (DAA) for both HBV and HCV has remarkably improved the standard of treatment for both infections. While HCV can be eliminated following combination DAA therapy, HBV persists even after treatment, requiring life-long therapy with DAAs. Treatment with DAAs is also associated with high cost, the development of resistance and side effects. There is ample published evidence that both HBV and HCV can be eliminated from infected host cells through non-cytolytic immune mechanisms. We need to identify the mechanisms behind this successful elimination of replicating viruses and develop them into novel immunotherapeutic regimens. Moreover, a synergy of, chemo- and immuno-therapeutic strategies will be necessary to eradicate HBV or HCV from a host.

• Authors: Babita Agrawal, Rakesh Kumar
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 22 Issue 25 Pg. 5623-6 (Jul 07 2016) ISSN: 2219-2840 [Electronic] United States
• PMID: 27433078 (Publication Type: Editorial)

Chemical References

• Antiviral Agents
• Immunologic Factors

Topics

• Antiviral Agents (pharmacology, therapeutic use)
• Drug Therapy, Combination
• Hepacivirus (drug effects)
• Hepatitis B virus (drug effects)
• Hepatitis B, Chronic (drug therapy)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Immunologic Factors (pharmacology, therapeutic use)
• Virus Replication (drug effects)